The best and the worst drugs approved by FDA in 2015


Novel Drug Approvals for 2015 (Image courtesy of jk1991 at


According to FierceBiotech, in 2015 Food and Drug Agency (FDA) approved 45 new drugs. It's the largest number since 1996. Here we present the summary of Big Pharma companies having last year the highest success with new drug approvals (in terms of potential sales revenue).

Number one is Novartis with 4 new drugs. Among them two blockbusters are worth to mention: Entresto (for heart failure with preserved ejection fraction) and Cosentyx for psoriasis. Only for Entresto the peak sales are estimated for more than $5 billion. The second in the stage is Sanofi with Praluent (alirocumab, PCSK9 blocking antibody) lowering LDL cholersterol and the peak sales estimate about $3 billion. Another notable high scoring companies are:

  • Amgen with Repatha (evolocumab) also PCSK9 blocking antibody, peak sales estimate $3 billion, and Corlanor for angina;
  • AstraZeneca with two approvals, among them Tagrisso (osimertinib) for advanced non-small cell lung cancer, peak sales estimate $3 billion;
  • Pfizer and its Ibrance (palbociclib) for breast cancer, peak sales estimate: $3 to $5 billion;
  • Johnson & Johnson with Darzalex (daratumumab) for the multiple myeloma;
  • and Novo Nordisk with long-acting insulin Tresiba for diabetes.

At the end of the line are Eli Lilly with approval for costly and not very effective oncologic drug Portrazza and Merck with approval for Bridion, which finally got FDA approval after three rejections.

FDA website: Novel Drug Approvals for 2015
Image credits: jk1991
Image source:
Feel free to contact us.


Phone: +48 71 725 34 10

Office address
ul. E. Kwiatkowskiego 4, 52-326 Wrocław, Poland

© 2020 - Grupa Kapitałowa Startit Fund | All rights reserved.

Made in:

Important: I hereby confirm that I have read the Privacy Policy and Cookies Policy of Startit Fund Sp. z o.o. [Ltd.] company
Join us!